Erschienen in:
22.07.2016 | Bench to Bedside
Bench to Bedside: Platelet-rich Plasma—How Do We Adequately “Untranslate” Translational “Breakthroughs” in an After-market Setting?
verfasst von:
Benjamin K. Potter, MD
Erschienen in:
Clinical Orthopaedics and Related Research®
|
Ausgabe 10/2016
Einloggen, um Zugang zu erhalten
Excerpt
While most of my
Bench to Bedside columns focus on topics that are poised to jump from the laboratory to popular clinical practice (or soon will be), it seems important to “untranslate” something that may have infiltrated practice far ahead of adequate evidence—platelet-rich plasma (PRP). Defined simply as “a sample of autologous blood with concentrations of platelets above baseline value” [
8], PRP is ostensibly rich in proteins such as platelet-derived growth factor, vascular endothelial growth factor, and human growth factor. Fibrinogen has also been detected at high concentrations in PRP. …